https://www.selleckchem.com/products/sbi-477.html
The current standard of care for the management of patients with newly diagnosed glioblastoma (GBM) includes maximal safe resection followed by radiotherapy (RT) with concurrent and adjuvant temozolomide (TMZ). While it is well established that TMZ has better efficacy in patients with promoter methylation, it remains an area of debate whether TMZ should be omitted when treating GBM patients with unmethylated . We conducted a systematic review and meta-analysis to provide separate estimates of median overall survival (OS) and progression
Like
Comment
Share
